Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant inherited disorders affecting the nervous system. NF1 is associated with mutations in the NF1 gene, which is located on chromosome sub-band 17q11.2 and contains 57 exons spanning approximately 300 kb of genomic DNA. NF1 is caused by a loss of function mutation of the NF1 gene, a tumor suppressor gene, which encodes for neurofibromin, a GTPase-activating protein (GAP) involved in the negative regulation of Ras activity. The GAP-related domain, which is encoded for by exons 20-27a, is one of the most important functional domains in neurofibromin. The cysteine-serine-rich domain has been recognized as an important functional domain in NF1-related pheochromocytomas. As the result of many genetic analyses of NF1-related pheochromocytomas, pheochromocytoma has generally been recognized as a true component of NF1. We recently experienced two families with NF1 accompanied by pheochromocytoma. The proband of family 1 is a 31-year-old female diagnosed with NF1 and pheochromocytoma. Gene analysis of the proband and her sister showed that the mutation of the NF1 gene (c.7907+1G>A) led to the skipping of exon 53 during NF1 mRNA splicing. The proband of family 2 is a 48-year-old male who was diagnosed with the same condition. Gene analysis demonstrated the mutation of the NF1 gene (c.5206-8C>G) with missplicing of exon 37. These novel germline mutations did not fall into the GAP-related nor the cysteine-serine-rich domains, but into the C-terminal area of the NF1 gene. This suggests that the correlation between the genotype and phenotype of NF1-related pheochromocytoma is somewhat difficult to characterize. Further studies will be necessary to confirm the function of the C-terminal area of the NF1 gene and its contribution to the development of NF1 and pheochromocytoma. (Endocrinol Metab 26:177-184, 2011) 
INTRODUCTION
Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant inherited disorder affecting the nervous system and is associated with mutations in the NF1 gene. The cardinal features of NF1 are multiple dermal neurofibromas, café-au-lait spots, axillary or inguinal freckling, and hamartomas of the iris (Lisch nodules). NF1 is diagnosed by clinical criteria initially established by the National Institutes of Health Consensus Development Conference in 1988 and the criteria was revised by Gutmann et al. [2] in 1997.
The NF1 gene is located on chromosome sub-band 17q11.2 and contains 57 exons spanning approximately 300 kb of genomic DNA ( Fig. 1) , and is transcribed to an mRNA of 11-13 kb that encodes for a protein, neurofibromin, of 2818 amino acids [3] . NF1 is caused by a loss of function of the NF1 gene, a tumor suppressor gene, which encodes neurofibromin, a GTPase activating protein involved in the negative regulation of Ras activity. Therefore, a neurofibromin deficiency results in hyperactivation of Ras, which is associated with cell proliferation and differentiation. GTPase activating protein-related domain (GRD), which is encoded by exons 20-27a, is one of the most important functional domains in neurofibromin. The interaction of Ras-GRD stimulates GTP hydrolysis which can mediate the regulation of cell proliferation and apoptosis. However, there are few studies about C-terminal region of NF1 gene and it has also yet to be known about the function of C-terminal area of NF1 gene.
In Korea, Jeong et al. [7] reported the spectrum of NF1 mutations in Korean NF1 patients, and discussed a genotype-phenotype cor-http://www.enm-kes.org relation analysis in 2006. In the report, there was no detected mutation in C-terminal region, but most of mutations were found in GRD and cAMP protein kinase recognition sites (cAMP/PK).
We recently experienced two families of NF1 accompanied by pheochromocytoma and the mutations of two families have been found in C-terminal region of NF1 gene. Therefore, we performed the genetic analysis of the NF1 gene to verify the genotype-phenotype correlation in NF1 associated with pheochromocytoma.
CASE REPORT

Patients
1) Family 1 (1) Proband
A 31-year-old woman suffered from intermittent paroxysmal headaches and chest discomfort. However, there were no abnormalities on the cardiologic evaluations and no improvement in the symptoms, despite continuous medication for 1 year. Finally, the patient was admitted to the hospital for evaluation of secondary hypertension. Based on history and clinical examination, the patient's sister and father were diagnosed with NF1 (Fig. 2) . The physical examination revealed café-au-lait spots on the back and lower extremities and axillary freckling. We diagnosed her as NF1 by the clinical criteria. 10-65 pg/mL) and 4.91 pg/mL (normal, 0-10 pg/mL), respectively.
Moreover, we confirmed a 4.0-cm well-enhancing mass in the left adrenal gland by abdominal computed tomography scan (Fig. 3A) .
Based on the results, we diagnosed the patient of a pheochromocytoma accompanied by NF1.
The patient underwent a left adrenalectomy and was evaluated for pheochromocytoma-associated syndrome with thyroid sonography, fundoscopic exam, brain magnetic resonance imaging (MRI), positron emission tomography, and a parathyroid hormone level.
The results of almost all tests were negative, but the brain MRI revealed multiple subtle high signals on T2-weighted images and low signals on T1-weighted images in the left temporal lobe. The lesion was suspected to be a dysembryoplastic neuroepithelial tumor based on the imaging studies. As the location of the tumor was difficult to approach surgically, the patient has only been observed periodically.
(2) Sister
A 29-year-old woman was diagnosed with NF1 in 15 years ago.
The patient had suffered from multiple plexiform neurofibromas involving both axillae (Fig. 4A) . The neurofibromas continued to increase in number and size throughout adulthood, causing stinging, itching, pain, and disfiguration. Unlike her sister, she did not have hypertension or a pheochromocytoma. There were no other ocular or systemic diseases associated with NF1. The patient underwent surgery for disfigurated and symptomatic neurofibroma. 
Methods
The following gene analyses and fibroblast cultures were performed with written informed consent to confirm whether or not the patients or their family members had germline mutations. The study was approved by Institutional Review Board of Gachon University Gil Hospital, Korea.
Comprehensive NF1 mutation analysis
Comprehensive NF1 mutation analysis starts with extraction of DNA from the patient's blood sample. Another aliquot of the blood sample is used to start a short-term culture of phytohaemagglutininstimulated lymphocytes. Total RNA is extracted from puromycintreated cultures and cDNA is prepared. 5. NF1 mutation producing splicing defects and affecting truncated protein
1) Family 1
The patient and her family members exhibited mutations involving the splice site in lymphocytes and adrenal tissues (Fig. 6A) . No other possible damaging alteration was detected after comprehensive NF1 mutation analysis. This finding confirmed the diagnosis of NF1 in this patient. The detected point mutation (c.7907+1G>A) caused skipping of exon 53 (Fig. 6B ). In the process of translation, the mutation, c.7907+1G>A, made a terminal codon (TAA) during mRNA splicing and 53 exon skipping caused premature termination of protein translation.
2) Family 2
The point mutation (c.5206-8C>G) was detected and that is out of frame for splicing of exon 37 caused by mutation of NF1 gene (Fig. 7A) . This alteration creates a novel splice acceptor that is used in lieu of the native splice acceptor, and an out of frame insertion of intronic sequence into the NF1 mRNA occurs (Fig. 7B ). http://www.enm-kes.org dent adenylyl cyclase signaling. The latter pathway is necessary for part of the C-terminal residues downstream of the GAP-related domain. In fact, reconstitution of the NF1-GAP-related domain can result in a partial restoration of cAMP levels in NF1 -/-astrocytes.
Therefore, we suggest that another region of the NF1 gene, rather than the GAP-related domain is associated with formation of the tumor or signal transduction pathway which can control angiogenic factor expression.
The suitability of using antisense morpholino oligomers (AMO)
to restore the aberrant splicing caused by deep intronic mutations in the NF1 gene has been reported. The authors showed corrected aberrant splicing and increased levels of wild-type NF1 transcripts with AMO treatment. Moreover, they revealed that correction of aberrant NF1 splicing decreased the active Ras-GTP levels in primary fibroblasts, which is consistent with the restoration of neurofibromin GTPase activity to wild-type levels.
We detected germline NF1 mutations in patients with a pheochromocytoma displaying the NF1 phenotype; they are novel mutations which are thought to be related to pheochromocytomas. Further studies are needed to clarify the genotype-phenotype correlations of pheochromocytoma occurred as a component of NF1. 
